These recalls got a lot of media attention, but the biggest recall of all in 2018 got little, according to Sam Bloch, a reporter for The New Food Economy, who wrote “The biggest food recall of 2018 is one you still haven’t heard about.” Continue reading
In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.
The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.
The problem is a unique business and policy dilemma for society. Continue reading
A recent report on the results of a series of unannounced “vape shop” visits by federal inspectors raises questions about quality-assurance in the preparation of some e-cigarette products.
Vape shops typically sell products, including electronic nicotine delivery devices and “e-liquids” solutions that are atomized by heating elements within the devices. When inhaled, the resulting vapor delivers nicotine, flavorings and other additives to the user. Continue reading
If you are familiar with Drugs@FDA, you know that the website allows you to quickly look up a drug by its name (brand), the active ingredient (generic), or application number. But if you frequently work on the go or need to look up something quickly while away from your computer, you now can download the FDA’s new app, Drugs@FDA Express (iOS/Apple and Android/Google), to see much of the same information.
Released in late March, the app is pretty basic, but often that’s the best kind of app. It loads quickly, isn’t overly cluttered and has simpler user-friendly interface. The opening page is straightforward. Continue reading
Health insurers struggle to understand whether genetic tests give physicians actionable information about how to diagnose and treat patients’ illness. If health insurers struggle, then journalists certainly will as well. For example, see this tip sheet that Beth Daley (@BethBDaley) wrote for AHCJ when she was at the New England Center for Investigative Reporting.
Genetic testing holds immense promise, but as speakers explained during the “Science of Genetic Testing” session at Health Journalism 2018, misuse and misinterpretation of these tests have undercut that promise. Continue reading
After decades of unfulfilled promises and setbacks, the field of gene therapy broke through with three FDA-approved products last year, ushering in what is likely to be a rapid escalation of new treatments for some of the rarest and most debilitating diseases.
“Part of the idea of the Human Genome project was that once we had the identity of all the genes, it would be important and straight forward for us to development more therapeutic options for people with serious inherited diseases, said Katherine High, M.D., president and director of research and development for Philadelphia-based Spark Therapeutics. “But it turned out this took a little longer to do than the Human Genome project.” Continue reading